Pfizer Z Score

<div class='circular--portrait' style='background:#FF0F00;color: #FFFFF0;font-size:3em;padding-top: 38px;;'>PFE</div>
PFE -- USA Stock  

Report: 28th of July 2020  

Altman Z Score is one of the simplest fundamental models to determine how likely your company is to fail. The module uses available fundamental data of a given equity to approximate the Altman Z score. Altman Z Score is determined by evaluating five fundamental price points available from the company's current public disclosure documents. Please check Pfizer Piotroski F Score and Pfizer Valuation analysis.

Search Z Score

 
Refresh
The current year Market Capitalization is expected to grow to about 225.4 B, whereas Capital Expenditure is expected to decline to (2.8 B). Pfizer Net Income to Non Controlling Interests is expected to increase significantly based on the last few years of reporting. The past year's Net Income to Non Controlling Interests was at 29 Million. The current year Operating Income is expected to grow to about 12.4 B, whereas Cost of Revenue is expected to decline to about 9.9 B.

Pfizer Z Score Analysis

Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
 2017 2018 2019 2020 (projected)
Consolidated Income21.36 B11.19 B16.3 B15.73 B
Direct Expenses11.24 B11.25 B10.22 B12.13 B
Z Score 
 = 
Sum Of  
 
5 Factors 
More About Z Score | All Equity Analysis

Current Pfizer Inc Z Score

1.8
First Factor
 = 
1.2 * (
Working Capital
/
Total Assets )
Second Factor
 = 
1.4 * (
Retained Earnings
/
Total Assets )
Thrid Factor
 = 
3.3 * (
EBITAD
/
Total Assets )
Fouth Factor
 = 
0.6 * (
Market Value of Equity
/
Total Liabilities )
Fifth Factor
 = 
0.99 * (
Revenue
/
Total Assets )

Pfizer Distress Driver Correlations

About Z Score

To calculate Z-Score one would need to know current working capital of the company, its total assets, and liabilities, amount of latest retained earnings as well as earnings before interest and tax. Z-Score can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area' with scores of less than 1 indicating the high probability of distress. Z Score is used widely by financial auditors, accountants, money managers, loan processers, wealth advisers, as well as day traders. In the last 25 years, many financial models that utilize z score has been proved to be successful as a predictor of corporate bankruptcy.
Compare to competition

  Accumulated Other Comprehensive Income

Pfizer Inc has Z Score of 1.8. This is 73.33% lower than that of the Healthcare sector, and significantly higher than that of Drug Manufacturers?General industry, The Z Score for all stocks is 79.36% higher than the company.

Did you try this?

Run Idea Analyzer Now

   

Idea Analyzer

Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
All  Next Launch Module

PfizerCurrent Valuation Drivers

2014201520162017201820192020 (projected)
Revenue Per Employee633.52 K498.99 K545.9 K582.55 K580.6 K586.07 K655.69 K
Average Assets170.84 B164.94 B170.91 B170.32 B164.21 B162.39 B158.48 B
Earnings before Tax12.26 B8.95 B8.34 B12.26 B11.86 B17.66 B17.1 B
Average Equity75.92 B66.44 B62.17 B62.22 B68.67 B61.66 B63.18 B
Enterprise Value230.88 B235.06 B239.08 B257.07 B289.8 B266.7 B273.97 B
Free Cash Flow15.5 B13.19 B14.19 B14.59 B13.63 B9.99 B11.24 B
Invested Capital102.08 B84.64 B72.89 B78.83 B79.54 B87.01 B84.82 B
Tangible Asset Value90.33 B78.78 B64.52 B67.1 B70.8 B73.47 B73.9 B
Working Capital34.01 B14.4 B7.83 B10.71 B18.07 B(4.5 B)(4.62 B)
Interest Coverage13.7813.012.4214.6111.787.679.09
Calculated Tax Rate25.4922.213.45(73.539212)5.947.839.52
PPandE Turnover4.113.833.893.873.943.783.59
Receivables Turnover5.55.86.426.396.66.185.59
Inventory Turnover1.621.461.721.571.491.291.59
Operating Margin25.9819.3716.8424.4421.5819.9719.72
Return on Investment11.678.948.6711.8710.539.3811.02
Cash Flow Per Share2.682.352.622.752.772.272.24
Quick Ratio1.792.071.070.840.930.50.51
Book Value per Share11.2410.489.7811.9410.811.3410.64
Current Ratio2.671.491.251.351.570.880.9
Debt to Equity Ratio0.510.60.710.610.660.830.68
EBITDA Margin34.727.4724.8434.1533.1145.6837.74

Pfizer Institutional Holders

Current Institutional Investors

Security TypeSharesValue
Confluence Investment Management LlcCommon Shares2.3 M76.1 M
Park National CorpCommon Shares470.4 K15.4 M
First Financial BanCommon Shares201 K6.6 M
Pensionfund Dsm NetherlandsCommon Shares150.8 K4.9 M
Pensionfund SabicCommon Shares109.1 K3.6 M
Thomasville National BankCommon Shares88.2 K2.9 M
Boltwood Capital ManagementCommon Shares73.6 K2.4 M

Pfizer Fundamentals

About Pfizer Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Pfizer Inc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pfizer using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pfizer Inc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way. Please read more on our fundamental analysis page.
 2017 2018 2019 2020 (projected)
Receivables8.22 B8.03 B8.72 B10.38 B
Inventories7.58 B7.51 B8.28 B7.42 B


 
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page